1. Home
  2. LYRA vs AQMS Comparison

LYRA vs AQMS Comparison

Compare LYRA & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • AQMS
  • Stock Information
  • Founded
  • LYRA 2005
  • AQMS 2014
  • Country
  • LYRA United States
  • AQMS United States
  • Employees
  • LYRA N/A
  • AQMS N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • AQMS Metal Fabrications
  • Sector
  • LYRA Health Care
  • AQMS Industrials
  • Exchange
  • LYRA Nasdaq
  • AQMS Nasdaq
  • Market Cap
  • LYRA 13.5M
  • AQMS 14.0M
  • IPO Year
  • LYRA 2020
  • AQMS 2015
  • Fundamental
  • Price
  • LYRA $0.21
  • AQMS $2.29
  • Analyst Decision
  • LYRA Buy
  • AQMS Strong Buy
  • Analyst Count
  • LYRA 5
  • AQMS 2
  • Target Price
  • LYRA $4.50
  • AQMS $30.00
  • AVG Volume (30 Days)
  • LYRA 907.8K
  • AQMS 110.0K
  • Earning Date
  • LYRA 03-20-2025
  • AQMS 03-26-2025
  • Dividend Yield
  • LYRA N/A
  • AQMS N/A
  • EPS Growth
  • LYRA N/A
  • AQMS N/A
  • EPS
  • LYRA N/A
  • AQMS N/A
  • Revenue
  • LYRA $1,471,000.00
  • AQMS N/A
  • Revenue This Year
  • LYRA N/A
  • AQMS N/A
  • Revenue Next Year
  • LYRA N/A
  • AQMS N/A
  • P/E Ratio
  • LYRA N/A
  • AQMS N/A
  • Revenue Growth
  • LYRA 3.37
  • AQMS 525.00
  • 52 Week Low
  • LYRA $0.16
  • AQMS $1.33
  • 52 Week High
  • LYRA $6.79
  • AQMS $14.14
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 57.63
  • AQMS 53.75
  • Support Level
  • LYRA $0.19
  • AQMS $1.92
  • Resistance Level
  • LYRA $0.22
  • AQMS $2.82
  • Average True Range (ATR)
  • LYRA 0.01
  • AQMS 0.24
  • MACD
  • LYRA 0.00
  • AQMS 0.06
  • Stochastic Oscillator
  • LYRA 66.75
  • AQMS 53.88

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About AQMS Aqua Metals Inc.

Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.

Share on Social Networks: